Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2018, Article ID 4248971, 10 pages
https://doi.org/10.1155/2018/4248971
Research Article

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

1Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
2Beijing Novogene Bioinformatics Technology Co., Ltd., Beijing, China
3Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
4Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Correspondence should be addressed to Mulan Jin; moc.361@narukomnik, Gang Cheng; moc.enegovon@gnehc.ffej, and Guangyu An; moc.liamtoh@uygnaugna

Received 8 November 2017; Accepted 31 January 2018; Published 7 March 2018

Academic Editor: Kiran L. Sharma

Copyright © 2018 Jiannan Yao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Jiannan Yao, Wanchun Zang, Yang Ge, et al., “RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients,” Canadian Journal of Gastroenterology and Hepatology, vol. 2018, Article ID 4248971, 10 pages, 2018. https://doi.org/10.1155/2018/4248971.